Novo Nordisk

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments.

CEO

Maziar Mike Doustdar

CEOMaziar Mike Doustdar

Employees

68,794

Employees68,794

Headquarters

Bagsværd, Capital Region

HeadquartersBagsværd, Capital Region

Founded

1923

Founded1923

Employees

68,794

Employees68,794

NVO Key Statistics

Market cap

200.26B

Market cap200.26B

Price-Earnings ratio

10.57

Price-Earnings ratio10.57

Dividend yield

2.73%

Dividend yield2.73%

Average volume

13.66M

Average volume13.66M

High today

$44.84

High today$44.84

Low today

$43.74

Low today$43.74

Open price

$44.18

Open price$44.18

Volume

7.97M

Volume7.97M

52 Week high

$81.44

52 Week high$81.44

52 Week low

$35.12

52 Week low$35.12

NVO News

Simply Wall St 1h

Novo Nordisk Turns To OpenAI To Tighten Drug Development And Supply Chain

Novo Nordisk (NYSE:NVO) has announced a new partnership with OpenAI to embed artificial intelligence across drug discovery, manufacturing, and supply chain oper...

MarketWatch 3h

Canada and India now have generic Wegovy. Here’s why the U.S. doesn’t.

There are now highly anticipated generic versions of Novo Nordisk’s GLP-1 blockbusters, Ozempic and Wegovy, on the Canadian market. Several generic versions ha...

The Motley Fool 7h

Could Viking Therapeutics Be the Next Eli Lilly?

Eli Lilly (LLY 0.52%) wasn't the first to conquer the weight loss drug market. Novo Nordisk started the ball rolling back in 2017, when it won approval for its...

Analyst ratings

58%

of 36 ratings

Buy

33.3%

Hold

58.3%

Sell

8.3%

More NVO News

Nasdaq 15h

Best Weight Loss Drug Stocks to Buy in 2026

Key Points Demand for weight-loss drugs has exploded, with material differentiation among the players in the niche. There's a clear leader, but that may not b...

Simply Wall St 2d

Wegovy Liver Data Broadens Semaglutide Story For Novo Nordisk Investors

Novo Nordisk (NYSE:NVO) reported new semaglutide (Wegovy) data at the EASL 2026 congress on liver safety and efficacy in chronic liver disease. The trials focu...

TipRanks 2d

Novo Nordisk Advances New Cagrilintide Study in the Race for Obesity Leadership

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decision...

TipRanks 2d

Novo Nordisk’s AMAZE 2 Trial: A New Weight-Loss Shot Targets Growth Beyond Semaglutide

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decision...

The Motley Fool 3d

Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party

Eli Lilly (LLY 1.61%) and Novo Nordisk (NVO 0.93%) dominate the weight-loss drug market and have for a while. What's more, recent launches are helping them expa...

The Motley Fool 3d

Eli Lilly Stock: Next Stop $2,000?

It's been a volatile year for Eli Lilly (LLY 1.61%). The company's shares trended lower through the end of April, dropping well below $900. However, the drugmak...

24/7 Wall St. 3d

Three Biotechs That Are Top Takeover Targets

Three Biotechs That Are Top Takeover Targets By Alex Sirois Published May 18, 1:55PM EDT Quick Read Viking Therapeutics (VKTX) has a dual GLP-1/GIP agonist in...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.